Type II P21-activated Kinases (PAKs) Are Regulated by an Autoinhibitory Pseudosubstrate
Overview
Authors
Affiliations
The type II p21-activated kinases (PAKs) are key effectors of RHO-family GTPases involved in cell motility, survival, and proliferation. Using a structure-guided approach, we discovered that type II PAKs are regulated by an N-terminal autoinhibitory pseudosubstrate motif centered on a critical proline residue, and that this regulation occurs independently of activation loop phosphorylation. We determined six X-ray crystal structures of either full-length PAK4 or its catalytic domain, that demonstrate the molecular basis for pseudosubstrate binding to the active state with phosphorylated activation loop. We show that full-length PAK4 is constitutively autoinhibited, but mutation of the pseudosubstrate releases this inhibition and causes increased phosphorylation of the apoptotic regulation protein Bcl-2/Bcl-X(L) antagonist causing cell death and cellular morphological changes. We also find that PAK6 is regulated by the pseudosubstrate region, indicating a common type II PAK autoregulatory mechanism. Finally, we find Src SH3, but not β-PIX SH3, can activate PAK4. We provide a unique understanding for type II PAK regulation.
Iannotta L, Fasiczka R, Favetta G, Zhao Y, Giusto E, DallAra E Cell Death Dis. 2024; 15(10):752.
PMID: 39419978 PMC: 11487180. DOI: 10.1038/s41419-024-07124-4.
P-21 Activated Kinases in Liver Disorders.
Qiu X, Xu H, Wang K, Gao F, Xu X, He H Cancers (Basel). 2023; 15(2).
PMID: 36672500 PMC: 9857091. DOI: 10.3390/cancers15020551.
Rho family GTPase signaling through type II p21-activated kinases.
Chetty A, Ha B, Boggon T Cell Mol Life Sci. 2022; 79(12):598.
PMID: 36401658 PMC: 10105373. DOI: 10.1007/s00018-022-04618-2.
Molecular basis for integrin adhesion receptor binding to p21-activated kinase 4 (PAK4).
Ha B, Yigit S, Natarajan N, Morse E, Calderwood D, Boggon T Commun Biol. 2022; 5(1):1257.
PMID: 36385162 PMC: 9669019. DOI: 10.1038/s42003-022-04157-3.
p21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond.
Li X, Li F Cancers (Basel). 2022; 14(19).
PMID: 36230657 PMC: 9563254. DOI: 10.3390/cancers14194736.